Abstract
IC351 (Cialis™) is a selective inhibitor of PDE5. The efficacy and safety of on-demand dosing of IC351 in men with erectile dysfunction was assessed in a multicenter, double-blind, placebo-controlled study. One hundred seventy-nine men (mean age: 56 y) were randomized to receive placebo or IC351 at doses of 2, 5, 10 or 25 mg, taken on demand over a 3-week period. The primary endpoints were change from baseline in responses to Questions 3 (Q3) and 4 (Q4) of the International Index of Erectile Function (IIEF). IC351 significantly improved IIEF Q3 scores at all doses vs placebo (P≤0.003). IC351 also significantly improved IIEF Q4 scores in all but the 2 mg group (P≤0.0003). No significant changes in laboratory values, ECGs, or blood pressure were observed. The most common adverse events were headache and dyspepsia. The conclusion of this study was that on-demand IC351 at doses up to 25 mg was well tolerated and significantly improved erectile function.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Padma-Nathan, H., McMurray, J., Pullman, W. et al. On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 13, 2–9 (2001). https://doi.org/10.1038/sj.ijir.3900631
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3900631
Keywords
This article is cited by
-
Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson’s Disease?
Molecular Neurobiology (2018)
-
Patients’ preference in the treatment of erectile dysfunction: a critical review of the literature
International Journal of Impotence Research (2011)
-
Twenty years of IJIR
International Journal of Impotence Research (2008)
-
Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying the common pathophysiologic link
International Journal of Impotence Research (2008)
-
Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
International Journal of Impotence Research (2007)